Navamedic ASA
OSE:NAVA
Net Margin
Navamedic ASA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| NO |
N
|
Navamedic ASA
OSE:NAVA
|
370.9m NOK |
-2%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.7B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Navamedic ASA
Glance View
Navamedic ASA engages in the delivery and marketing of pharmaceutical products to patients, hospitals, and pharmacies. The company is headquartered in Oslo, Oslo. The company went IPO on 2006-03-31. The firm in-licenses, acquires and markets pharmaceuticals and other healthcare products in northern Europe. The product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices and other healthcare products. Navamedic ASA has three subsidiaries: Observe Medical, a Swedish medical technology company; Vitaflo Scandinavia AB, which focuses on in-licensing and buying pharmaceuticals and other healthcare products within a few selected knowledge areas; and Navamedic ehf, which builds its business around the sales and marketing of generic pharmaceuticals targeted towards the Nordic and BeNeLux markets. The Navamedic business unit is built upon the cooperation with the South African pharmaceutical company Aspen Healthcare. The Company’s largest shareholder is Nobelsystem Scandinavia.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Navamedic ASA's most recent financial statements, the company has Net Margin of -2.1%.
You don't have any saved screeners yet